[go: up one dir, main page]

UY33154A - Metodo para disminuir la unmunogenicidad - Google Patents

Metodo para disminuir la unmunogenicidad

Info

Publication number
UY33154A
UY33154A UY0001033154A UY33154A UY33154A UY 33154 A UY33154 A UY 33154A UY 0001033154 A UY0001033154 A UY 0001033154A UY 33154 A UY33154 A UY 33154A UY 33154 A UY33154 A UY 33154A
Authority
UY
Uruguay
Prior art keywords
decreasing
unmunogenicity
immunogenicity
antibody
disclosed
Prior art date
Application number
UY0001033154A
Other languages
English (en)
Inventor
Urech David
Gunde Tea
Leonardo Jose Borras
Original Assignee
Esbatech Alcon Biomed Res Unit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech Alcon Biomed Res Unit filed Critical Esbatech Alcon Biomed Res Unit
Priority to UY0001039290A priority Critical patent/UY39290A/es
Publication of UY33154A publication Critical patent/UY33154A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se da a conocer un método para disminuir la inmunogenicidad de los dominios variables de un anticuerpo.
UY0001033154A 2009-12-23 2010-12-22 Metodo para disminuir la unmunogenicidad UY33154A (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY0001039290A UY39290A (es) 2009-12-23 2010-12-22 Un método para disminuir la inmunogenicidad de un fragmento de anticuerpo que comprende una cadena ligera variable y/o una cadena pesada variable

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28944609P 2009-12-23 2009-12-23

Publications (1)

Publication Number Publication Date
UY33154A true UY33154A (es) 2011-06-30

Family

ID=43733894

Family Applications (2)

Application Number Title Priority Date Filing Date
UY0001039290A UY39290A (es) 2009-12-23 2010-12-22 Un método para disminuir la inmunogenicidad de un fragmento de anticuerpo que comprende una cadena ligera variable y/o una cadena pesada variable
UY0001033154A UY33154A (es) 2009-12-23 2010-12-22 Metodo para disminuir la unmunogenicidad

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY0001039290A UY39290A (es) 2009-12-23 2010-12-22 Un método para disminuir la inmunogenicidad de un fragmento de anticuerpo que comprende una cadena ligera variable y/o una cadena pesada variable

Country Status (17)

Country Link
US (4) US8796425B2 (es)
EP (3) EP2516461A1 (es)
JP (6) JP5914353B2 (es)
KR (3) KR101758703B1 (es)
CN (2) CN102686608A (es)
AR (1) AR079700A1 (es)
AU (1) AU2010335950B2 (es)
BR (1) BR112012017051A2 (es)
CA (1) CA2777527C (es)
CL (1) CL2012001696A1 (es)
MX (2) MX352871B (es)
PH (1) PH12012500794A1 (es)
RU (1) RU2585534C2 (es)
TW (3) TWI633184B (es)
UY (2) UY39290A (es)
WO (1) WO2011075861A1 (es)
ZA (4) ZA201202299B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101671886B1 (ko) * 2008-06-25 2016-11-04 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
EP2307458B1 (en) * 2008-06-25 2018-04-11 ESBATech, an Alcon Biomedical Research Unit LLC Humanization of rabbit antibodies using a universal antibody framework
AU2009264564B2 (en) * 2008-06-25 2014-05-08 Novartis Ag Stable and soluble antibodies inhibiting TNFalpha
MX352871B (es) * 2009-12-23 2017-12-13 Esbatech Alcon Biomed Res Unit Método para disminuir inmunogenicidad.
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
KR20220114104A (ko) * 2011-06-23 2022-08-17 아블린쓰 엔.브이. 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US11009511B2 (en) 2014-05-16 2021-05-18 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
BR112016026773A2 (pt) 2014-05-16 2017-12-12 Ablynx Nv domínios variáveis de imunoglobulina aperfeiçoados
CN108350069B (zh) * 2015-10-30 2021-11-12 埃博灵克斯股份有限公司 针对il-23的多肽
RS60823B1 (sr) 2015-12-04 2020-10-30 Boehringer Ingelheim Int Biparatopski polipeptidi koji antagonizuju wnt signalizaciju u tumorskim ćelijama
CN109689684B (zh) 2016-07-06 2022-09-23 细胞基因公司 具有低免疫原性的抗体及其用途
BR112019022729A2 (pt) 2017-05-31 2020-05-19 Boehringer Ingelheim Int polipeptídeos que antagonizam sinalização da wnt em células de tumor
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
FR3088640A1 (fr) 2018-10-14 2020-05-22 Smart Diagnostix Pharma Nouveau polypeptide se liant specifiquement a la proteine p16
TW202128756A (zh) 2019-10-02 2021-08-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
WO2022136693A1 (en) 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
US20250051826A1 (en) 2021-12-13 2025-02-13 Heraeus Medical Gmbh Tests and methods for detecting bacterial infection
IL316376A (en) * 2022-05-06 2024-12-01 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
EP4273162A1 (en) * 2022-05-06 2023-11-08 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
EP4357778A1 (en) 2022-10-20 2024-04-24 Heraeus Medical GmbH Treatment of microbial infections diagnosed using the biomarker d-lactate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018792A1 (en) 1992-03-18 1993-09-30 Biomira Inc. Selective alteration of antibody immunogenicity
WO1998002462A1 (en) 1996-07-16 1998-01-22 Morphosys Gesellschaft Für Proteinoptimierung Mbh Immunoglobulin superfamily domains and fragments with increased solubility
BR0207283A (pt) * 2001-02-19 2004-08-17 Merck Patent Gmbh Anticorpos anti-egfr modificados com imunogenicidade reduzida
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
OA13234A (en) * 2003-08-13 2006-12-13 Pfizer Prod Inc Modified human IGF-1R antibodies.
AU2008267733B2 (en) * 2007-06-25 2013-11-14 Esbatech, An Alcon Biomedical Research Unit Llc Sequence based engineering and optimization of single chain antibodies
GB0802931D0 (en) * 2008-02-18 2008-03-26 Queen Mary & Westfield College Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
US8243678B2 (en) * 2008-03-10 2012-08-14 Motorola Mobility, Inc. Hierarchical pilot structure in wireless communication systems
EP2307458B1 (en) * 2008-06-25 2018-04-11 ESBATech, an Alcon Biomedical Research Unit LLC Humanization of rabbit antibodies using a universal antibody framework
AU2009264564B2 (en) * 2008-06-25 2014-05-08 Novartis Ag Stable and soluble antibodies inhibiting TNFalpha
SI2307455T1 (sl) * 2008-06-25 2017-07-31 Esbatech, An Alcon Biomedical Research Unit Llc Optimizacija topnosti imunoveziv
MX352871B (es) * 2009-12-23 2017-12-13 Esbatech Alcon Biomed Res Unit Método para disminuir inmunogenicidad.

Also Published As

Publication number Publication date
TWI633184B (zh) 2018-08-21
RU2012130945A (ru) 2014-01-27
ZA201706443B (en) 2020-12-23
JP2015131855A (ja) 2015-07-23
KR20120102061A (ko) 2012-09-17
JP2021153603A (ja) 2021-10-07
US8796425B2 (en) 2014-08-05
JP2013515460A (ja) 2013-05-09
CA2777527C (en) 2020-06-23
CN102686608A (zh) 2012-09-19
AU2010335950B2 (en) 2014-08-21
KR20170036137A (ko) 2017-03-31
AU2010335950A1 (en) 2012-07-19
EP4219545A1 (en) 2023-08-02
UY39290A (es) 2021-07-30
TW201125975A (en) 2011-08-01
RU2585534C2 (ru) 2016-05-27
US20110152505A1 (en) 2011-06-23
US20210214461A1 (en) 2021-07-15
US10781268B2 (en) 2020-09-22
EP2516461A1 (en) 2012-10-31
AR079700A1 (es) 2012-02-15
JP2019141071A (ja) 2019-08-29
CL2012001696A1 (es) 2013-03-08
MX352871B (es) 2017-12-13
CN109293768A (zh) 2019-02-01
MX2012005345A (es) 2012-06-08
US9803027B2 (en) 2017-10-31
JP2016094487A (ja) 2016-05-26
WO2011075861A1 (en) 2011-06-30
JP5914353B2 (ja) 2016-05-11
JP6815083B2 (ja) 2021-01-20
PH12012500794A1 (en) 2012-11-26
JP2017121254A (ja) 2017-07-13
US20150080555A1 (en) 2015-03-19
ZA201402145B (en) 2018-05-30
KR101758703B1 (ko) 2017-07-18
TW201925228A (zh) 2019-07-01
BR112012017051A2 (pt) 2017-12-05
TW201619383A (zh) 2016-06-01
US20180016350A1 (en) 2018-01-18
ZA201202299B (en) 2014-06-25
KR101721187B1 (ko) 2017-03-29
EP3498731A1 (en) 2019-06-19
ZA202006532B (en) 2022-04-28
CA2777527A1 (en) 2011-06-30
TWI662128B (zh) 2019-06-11
KR20170084357A (ko) 2017-07-19

Similar Documents

Publication Publication Date Title
UY33154A (es) Metodo para disminuir la unmunogenicidad
CY1123958T1 (el) Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης
CR20120184A (es) Anticuerpos monoclonales frente a progastrina y su usos
BR112013001669A2 (pt) componentes tibiais assimétricas para prótese de joelho.
BRPI1000007A2 (pt) método de reparar mancal de gerador de turbina de vento
BR112013032229A2 (pt) método de tratamento hidrocatalítico hidrotérmico de biomassa, e, composição
BR112012032043A2 (pt) método para a produção de metano a partir da biomassa
MX2013010475A (es) Composiciones inmunoterapeuticas de levadura-brachyuri.
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
BR112012020853A2 (pt) padrões de ligação para mantas fibrosas
BRPI0914239A2 (pt) método para produção de uma estrutura de parede anular
BRPI1012117A2 (pt) método para tratar pelo menos uma porção de um poço.
BRPI0923797A2 (pt) Método para produzir um éster.
BR112013024420A2 (pt) método para a produção de hidrocarbonetos aromáticos de um só anel
BR112012005591A2 (pt) Geração de sementes oleaginosas produzindo alto poliidroxibutirato.
BR112013029015A2 (pt) métodos para controlar a despolimerização de composições poliméricas
BR112013027726A2 (pt) instalação de poço submarino e método associado
BR112013011017A2 (pt) método de completação de um poço subterrâneo
BR112013007237A2 (pt) ''método para produzir um anticorpo anti-ig-1r''
BR112014000351A2 (pt) “método para tratamento prévio de biomassa lignocelulósica”
BR112013028039A2 (pt) composição de cimento
BR112013025784A2 (pt) suporte para remodelar porção cartilaginosa de uma orelha, aplicador para inserir o suporte na orelha e método para remodelar a orelha
EA201300432A1 (ru) Полые микросферы и способ получения полых микросфер
BR112013011429A2 (pt) método para a recuperação de óleo a partir da biomassa
ECSP11011190A (es) Anticuerpos monoclonales anti-rhd

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20210721